DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Abilify (Aripiprazole) - Summary



Increased Mortality in Elderly Patients with Dementia-Related Psychosis

Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks) in these patients revealed a risk of death in the drug-treated patients of between 1.6 to 1.7 times that seen in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. ABILIFY (aripiprazole) is not approved for the treatment of patients with dementia-related psychosis.



ABILIFY® (aripiprazole) is a psychotropic drug that is available as tablets for oral administration.

ABILIFY (aripiprazole) is indicated for the treatment of schizophrenia. The efficacy of ABILIFY in the treatment of schizophrenia was established in short-term (4- and 6-week) controlled trials of schizophrenic inpatients (see CLINICAL PHARMACOLOGY: Clinical Studies).

The efficacy of ABILIFY in maintaining stability in patients with schizophrenia who had been symptomatically stable on antipsychotic medications for periods of 3 months or longer, were discontinued from those other medications, and were then administered ABILIFY 15 mg/day and observed for relapse during a period of up 26 weeks was demonstrated in a placebo-controlled trial (see CLINICAL PHARMACOLOGY: Clinical Studies). The physician who elects to use ABILIFY for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION).
See all Abilify indications & dosage >>


Media Articles Related to Abilify (Aripiprazole)

FDA approves first generic Abilify to treat mental illnesses
Source: Bipolar News From Medical News Today [2015.04.30]
The U.S. Food and Drug Administration has approved the first generic versions of Abilify (aripiprazole).

First Generic Abilify Approved
Source: MedicineNet aripiprazole Specialty [2015.04.30]
Title: First Generic Abilify Approved
Category: Health News
Created: 4/29/2015 12:00:00 AM
Last Editorial Review: 4/30/2015 12:00:00 AM

Scientists identify schizophrenia's "Rosetta Stone" gene
Source: Genetics News From Medical News Today [2015.07.24]
Scientists have identified a critical function of what they believe to be schizophrenia's "Rosetta Stone" gene that could hold the key to decoding the function of all genes involved in the disease.

High blood levels of growth factor correlate with smaller brain areas in patients with schizophrenia
Source: Schizophrenia News From Medical News Today [2015.07.16]
High blood levels of a growth factor known to enable new blood vessel development and brain cell protection correlate with a smaller size of brain areas key to complex thought, emotion and behavior...

Rexulti Approved for Schizophrenia, Depression
Source: MedicineNet Depression Specialty [2015.07.14]
Title: Rexulti Approved for Schizophrenia, Depression
Category: Health News
Created: 7/13/2015 12:00:00 AM
Last Editorial Review: 7/14/2015 12:00:00 AM

more news >>

Published Studies Related to Abilify (Aripiprazole)

Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial. [2014]
CONCLUSION: The study demonstrated that aripiprazole, as well as risperidone, had

Systematic review of clinical trials of aripiprazole for treating attention deficit hyperactivity disorder. [2013]
This systematic review assesses the effectiveness and safety of aripiprazole for treating attention deficit hyperactivity disorder (ADHD). The databases of PubMed/MEDLINE and Google Scholar were searched...

A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette's disorder. [2013]
CONCLUSIONS: In comparison with placebo, aripiprazole was efficacious, generally

Early antipsychotic response to aripiprazole in adolescents with schizophrenia: predictive value for clinical outcomes. [2013]
CONCLUSIONS: Like adults with chronic schizophrenia, adolescents with early-phase

The effects of aripiprazole on the subscales of the Kellner Symptom Questionnaire in treatment resistant depression. [2013]
We have recently examined the efficacy of low-dose aripiprazole augmentation for major depressive disorder (MDD), with modest nonsignificant benefit found. In a secondary investigation, we examined whether aripiprazole resulted in improvement in four subscales (depression, anxiety, somatic symptoms, and hostility) of the Kellner Symptom Questionnaire (KSQ)...

more studies >>

Clinical Trials Related to Abilify (Aripiprazole)

The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression [Active, not recruiting]
The purpose of the study is to assess the safety and effectiveness of the combination of aripiprazole (Abilify) and selective serotonin reuptake inhibitors (SSRIs) in subjects with psychotic major depression.

Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (SFBRI) [Terminated]
This is the sister study to the BMS "Cognitive Improvement with Aripiprazole (Abilify)" study (LSUHSC #H04-022). Evaluation of cognitive ability in patients with schizophrenia or schizoaffective disorder both before and after a switch from risperidone, olanzapine, or risperidone Consta injections to aripiprazole may reveal some of the cognitive changes that correlate with the improved response, better side effect profile, and effects on other components of the negative symptom array. Further, examination of brain functional activity using functional magnetic resonance imaging (fMRI) during an episodic memory task, as well as behavioral performance and associated electroencephalographic (EEG) data of working memory and intermediate term verbal memory collected with the Sustained Attention and Memory Brain Function Test (SAM-BFT), may also provide data showing the neural correlates of these changes in cognition.

Aripiprazole in Late Life Bipolar Disorder [Completed]
The purpose of this research study is to analyze the effectiveness and tolerability of a new medication, aripiprazole (Abilify), in individuals age 50 years and older who have bipolar disorder (manic-depressive illness).

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia [Recruiting]
The purpose of the this trial is to evaluate the efficacy, safety, and tolerability of an intramuscular (IM) depot formulation of aripiprazole as maintenance treatment in patients with schizophrenia

The trial is designed into three treatment phases. Phase 1 is designed to allow for a subject to be converted from the current antipsychotic treatment to oral non-generic aripiprazole monotherapy (oral conversion phase from 4 to 6 weeks). During Phase 2 the subject will be stabilized on oral non-generic aripiprazole monotherapy. Once the subject is stabilized in Phase 2 (oral stabilization phase from minimum 8 weeks to maximum 28 weeks), they are eligible to be randomized into the double-blind IM depot maintenance phase, Phase 3. During Phase 3, the subject will be assessed for exacerbation of psychotic symptoms and impending relapse for up to 38 weeks.

Aripiprazole for Co-Morbid Schizophrenia and Cocaine Dependence [Recruiting]
The purpose of this study is to gather systematic clinical data on whether aripiprazole, a partial dopamine agonist, beneficially affects schizophrenia plus cocaine dependence (SCHZ+CD) subjects. Since aripiprazole has established effects against SCHZ, the study focuses on whether aripiprazole concurrently ameliorates co-morbid CD in SCHZ+CD sufferers compared to a standard typical antipsychotic treatment (perphenazine). The working hypothesis states that subjects in the aripiprazole treatment arm of the study will yield fewer cocaine positive urine specimens as compared to the perphenazine control arm.

more trials >>

Reports of Suspected Abilify (Aripiprazole) Side Effects

Weight Increased (234)Tardive Dyskinesia (173)Tremor (133)Dyskinesia (113)Akathisia (96)Drug Ineffective (83)Insomnia (81)Pregnancy (80)Psychotic Disorder (75)Suicidal Ideation (72)more >>


Based on a total of 8 ratings/reviews, Abilify has an overall score of 5.38. The effectiveness score is 7.25 and the side effect score is 7. The scores are on ten point scale: 10 - best, 1 - worst. Below are selected reviews: the highest, the median and the lowest rated.

Abilify review by 43 year old female patient

Overall rating:  
Effectiveness:   Highly Effective
Side effects:   No Side Effects
Treatment Info
Condition / reason:   depression/anxiety
Dosage & duration:   2 mg taken daily for the period of 3 months
Other conditions:   anxiety
Other drugs taken:   Lexapro
Reported Results
Benefits:   Within 1 week of taking the cocktail of Abilify and Lexapro, a extremely unorganized person....became organized. I am now able to remember appointment times, keep up with my daily responsibilities...it has been a lifesaver
Side effects:   no side effects have been noticed
Comments:   I take one pill of each 1st thing in the am.....I am feeling better than ever


Abilify review by 26 year old female patient

Overall rating:  
Effectiveness:   Marginally Effective
Side effects:   Severe Side Effects
Treatment Info
Condition / reason:   bipolar disorder
Dosage & duration:   15mg taken daily for the period of 12 weeks
Other conditions:   none
Other drugs taken:   Cymbalta, 90mg/daily
Reported Results
Benefits:   I didn't notice any benefit at all. Supposedly, it was to help keep my mood balanced. More than anything, I was focused on the very apparent and prevalent side effects.
Side effects:   A very uncomfortable inner restlessness was the worst side effect. I felt like I had to constantly get up and move around, but it didn't even help. I couldn't sit still, had major problems sleeping at night, AND started gaining weight.
Comments:   I was prescribed Abilify (15mg/daily) to assist in moderating my mood. In the three months I took it, I did not notice any significant improvement in mood stability, and DID notice majorly debilitating side effects. I finally convinced my doctor to wean me off of it, and I guarantee I will never go back!


Abilify review by 50 year old male patient

Overall rating:  
Effectiveness:   Ineffective
Side effects:   Severe Side Effects
Treatment Info
Condition / reason:   bipolar
Dosage & duration:   2mg to start taken once daily for the period of 2 days
Other conditions:   anxiety
Other drugs taken:   klonopin
Reported Results
Benefits:   None due to the short time taking drug.
Side effects:   Headache first morning at 4AM that was relieved with Excedrin. Migraine headache with vomiting that lasted 14 hours. Couldn't go to work that day and stopped taking it.
Comments:   Not much to tell. I was just starting treatment with Klonopin and Abilify with the goal of stopping Klonopin in 30 days and then seeing how Abilify was working.

See all Abilify reviews / ratings >>

Page last updated: 2015-07-24

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015